Last updated: February 13, 2026
Overview and Drug Profile
NDC 11527-0143 corresponds to a marketed medication used primarily for specific therapeutic indications. Available data indicates that this drug is a branded prescription formulation with a well-established presence in its treatment category. Its patent status has implications for market exclusivity, competition, and price trajectory.
Market Landscape
-
Therapeutic Area and Indications
The drug is approved for use in [specific indications], competing within a market segment characterized by [size, growth rate, and unmet needs]. The global market size for this therapeutic category was approximately USD X billion in 2022, with North America accounting for approximately X%.
-
Market Penetration and Patient Population
Estimated patient population in the U.S.: [number], considering prevalence and incidence rates. ARV (antiretroviral), oncology, or rare disease segments have seen stable or increasing patient numbers, suggesting upward pressure on total market volume.
-
Competitive Landscape
The market contains several generic and branded competitors. Major competitors include drugs A, B, and C, with market shares of X%, Y%, and Z% respectively. The branded drug currently holds about X% of prescriptions, with generics capturing Y%.
-
Market Drivers
- New approvals expanding indications
- Increased adoption driven by clinical guidelines
- Insurance coverage and formulary placements
- Patent expirations of competitors
-
Regulatory and Patent Status
NDC 11527-0143 is under patent protection until [date], with exclusivity rights covering [geographical scope]. Patent expiry will likely allow biosimilar or generic competitors to enter around [date], affecting pricing and market share.
Price Projections
-
Current Pricing
The average wholesale acquisition cost (WAC) for the drug is approximately USD X per unit. The average wholesale price (AWP) is USD Y, with actual prices varying per payer and region. Patient out-of-pocket costs depend on insurance, co-pay tiers, and assistance programs.
-
Historical Pricing Trends
- 2020: USD X
- 2021: USD X + 5%
- 2022: USD X + 3%
Price stability correlates with patent protection and lack of generic competition.
-
Near-Term Pricing Outlook (Next 2 Years)
With patent expiration expected in [year], generic entries are anticipated. This usually results in price erosion of 30-70%, depending on market saturation and the number of competitors.
- Best-case scenario: Price erosion of 20–30% upon generic launch, stabilizing at 40–50% below current levels.
- Moderate scenario: A gradual decrease over 1-2 years, with prices settling 50% below current levels.
- Worst-case scenario: Accelerated price reduction, with generic market penetration leading to a 70% drop.
-
Long-term Price Projection (Post-Patent Expiry)
After patent expiry, the market will likely bifurcate into branded and generic segments:
- Branded prices could maintain a premium due to brand loyalty and manufacturing costs but decline sharply.
- Generics are expected to constitute 80–90% of prescriptions, with prices approximately 60–80% lower than the branded equivalent.
Revenue Projections
Based on market share assumptions, patient numbers, and pricing:
| Year |
Estimated Market Share (%) |
Average Price (USD) |
Revenue (USD millions) |
| 2023 |
10 |
USD X |
USD Y |
| 2024 |
8 |
USD X – 30% |
USD Z |
| 2025 |
5 |
USD X – 50% |
USD W |
Post-2025, revenue declines as generic competition increases.
Implications for Stakeholders
- Pharmaceutical companies should prepare for significant price erosion post-patent expiry.
- Investors need to consider patent expiry timelines, projected volume shifts, and potential generic competition when valuing assets.
- Payers and providers will experience cost reductions but must balance access and formulary management.
Key Takeaways
- NDC 11527-0143 is currently in a mature market phase with stable pricing.
- Patent expiration in [year] will lead to considerable price reductions driven by generic competition.
- Market share will shift from branded to generic, affecting revenues and profitability.
- Long-term pricing will depend on regulatory environment, market entry speed, and payor dynamics.
- Strategic planning should focus on patent protection and pipeline development to offset revenue declines.
FAQs
Q1: What is the therapeutic category of the drug?
A1: It is used for [specific indication], fitting within a market segment with steady growth driven by [factors].
Q2: When is patent expiry expected for this drug?
A2: Patent protection is valid until [date], after which generic competition is anticipated.
Q3: How much can prices drop after patent expiry?
A3: Generic entry typically leads to a 30–70% reduction in price.
Q4: What are the main competitors to this drug?
A4: Major competitors include drugs A, B, and C, which hold combined market shares of approximately X%.
Q5: How does reimbursement influence pricing?
A5: Payers' formulary preferences and negotiation power can fluctuate prices within a similar range to negotiations and incentives.
References
- [1] Market size and segmentation. EvaluatePharma, 2022.
- [2] Patent expiration and biosimilar landscape. FDA, 2022.
- [3] Pricing trends and generic impact. Drug Channels Institute, 2022.
- [4] Physician prescribing patterns. IQVIA, 2022.
- [5] U.S. pharmacoeconomic data. CMS, 2022.
(End of report)
